FDA Broadens Pitolisant Label - Scorecard - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Clinical Scorecard: FDA Broadens Pitolisant Label

At a Glance

CategoryDetail
ConditionNarcolepsy with or without cataplexy
Key MechanismsSelective histamine 3 receptor antagonist and inverse agonist, believed to increase histamine synthesis and release.
Target PopulationPediatric and adult patients aged 6 years and older
Care SettingOutpatient clinical settings

Key Highlights

  • Only non-scheduled therapy approved for narcolepsy in the US.
  • Indicated for excessive daytime sleepiness and cataplexy.
  • Approved for pediatric patients aged 6 years and older.
  • Received orphan drug designation in 2010 and breakthrough therapy designation in 2018.
  • Narcolepsy affects approximately 170,000 people in the US.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of narcolepsy based on clinical criteria including excessive daytime sleepiness and cataplexy.

Management

  • Pitolisant can be prescribed for managing excessive daytime sleepiness and cataplexy.

Monitoring & Follow-up

  • Monitor for QT prolongation and adverse reactions such as insomnia, nausea, and anxiety.

Risks

  • Contraindicated in patients with hypersensitivity to pitolisant or severe hepatic impairment.

Patient & Prescribing Data

Patients with narcolepsy aged 6 years and older.

Efficacy believed to be mediated through histamine 3 receptor activity.

Clinical Best Practices

  • Assess for history of cardiac arrhythmias before prescribing.
  • Educate patients about potential side effects including insomnia and anxiety.
  • Consider alternative therapies for patients with known QT prolongation.

Related Resources & Content

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Autism Spectrum Disorder Linked to Distinct Urine Metabolite Pattern

Researchers proposed a new autism spectrum disorder phenotype characterized by elevated urinary microbially derived metabolites.

The Science of Listening

Why patient voices must shape rare disease innovation

Dual-Site Theta Burst Stimulation May Reduce Suicidal Ideation

Four-day treatment targeting the prefrontal cortex and cerebellum produced larger reductions in suicidal ideation scores than prefrontal stimulation alone in adolescents with major depressive disorder.